Nicola R. Harker

Nicola R. Harker

Auto-generated profile, based on publicly available information

Nicola R. Harker

GlaxoSmithKline 2 Immunology Research Unit Medicines Research Centre, Stevenage, United Kingdom

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2003 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
Jasper de BoerJasper de Boer
Jasper de Boer
AWAdam Williams
Adam Williams
GSGeorge Skavdis
George Skavdis
NHNicola Harker
Nicola Harker
MCMark Coles
Mark Coles
DKDimitris Kioussis
Dimitris Kioussis
Bacteriophage P1 Cre/loxP based systems can be used to manipulate the genomes of mice in vivo and in vitro, allowing the generation of tissue‐specific conditional mutants. Wehave generated mouse lines expressing Cre recombinase in hematopoietic tissues using the vav regulatory elements, or in lymphoid cells using the hCD2 promoter and locus control region (LCR). The R26R‐EYFP Cre reporter mouse line was used to determine the pattern of Cre expression in each line and enabled the assessment of Cre activity at a single‐cell level. Analysis showed that the vav promoter elements were able to direct Cre‐mediated recombination in all cells of the hematopoietic system. The hCD2 promoter and LCR on the other hand were able to drive Cre‐mediated recombination only in T cells and B cells, but not in other hematopoietic cell types. Furthermore, in the appropriate tissues, deletion of the floxed target was complete in all cells, thereby excluding the possibility of variegated expression of the Cre transgene. Both of these Cre‐transgenic lines will be useful in generating tissue‐specific gene deletions within all the cells of hematopoietic or lymphoid tissues.

24 April 2020 in Science
Verified
Journal Article
Closed access
PDF file
OGOmer Gilan
Omer Gilan
IRInmaculada Rioja
Inmaculada Rioja
KKKathy Knezevic
Kathy Knezevic
MBMatthew Bell
Matthew Bell
MYMiriam M. Yeung
Miriam M. Yeung
MDMark A. Dawson
Mark A. Dawson
Bromodomain inhibitors revisited: Bromodomain and extraterminal domain (BET) proteins contribute to the pathogenesis of cancer and immune diseases through their effects on transcriptional regulation. BET proteins contain two nearly identical bromodomains, BD1 and BD2, structural modules that have attracted great interest as targets for drug development. First-generation drugs that inhibited both BD1 and BD2 showed promising therapeutic activity in preclinical models but proved to be less efficacious in clinical trials. Gilan et al. took a different approach and designed drugs that selectively inhibited BD1 or BD2 (see the Perspective by Filippakopoulos and Knapp). They found that BD1 and BD2 inhibitors altered gene expression in different ways and that BD2 inhibitors had greater therapeutic activity than BD1 inhibitors in preclinical models of inflammation and autoimmune disease. Science , this issue p. 387 ; see also p. 367

30 January 2014 in Blood
Verified
Journal Article
Closed access
PDF file
ACAristeidis Chaidos
Aristeidis Chaidos
VCValentina Caputo
Valentina Caputo
KGKaterina Gouvedenou
Katerina Gouvedenou
BLBinbin Liu
Binbin Liu
IMIlaria Marigo
Ilaria Marigo
AKAnastasios Karadimitris
Anastasios Karadimitris
The bromodomain and extraterminal (BET) protein BRD2-4 inhibitors hold therapeutic promise in preclinical models of hematologic malignancies. However, translation of these data to molecules suitable for clinical development has yet to be accomplished. Herein we expand the mechanistic understanding of BET inhibitors in multiple myeloma by using the chemical probe molecule I-BET151. I-BET151 induces apoptosis and exerts strong antiproliferative effect in vitro and in vivo. This is associated with contrasting effects on oncogenic MYC and HEXIM1, an inhibitor of the transcriptional activator P-TEFb. I-BET151 causes transcriptional repression of MYC and MYC-dependent programs by abrogating recruitment to the chromatin of the P-TEFb component CDK9 in a BRD2-4–dependent manner. In contrast, transcriptional upregulation of HEXIM1 is BRD2-4 independent. Finally, preclinical studies show that I-BET762 has a favorable pharmacologic profile as an oral agent and that it inhibits myeloma cell proliferation, resulting in survival advantage in a systemic myeloma xenograft model. These data provide a strong rationale for extending the clinical testing of the novel antimyeloma agent I-BET762 and reveal insights into biologic pathways required for myeloma cell proliferation. Key Points I-BET151 and I-BET-762 induce cell cycle arrest and apoptosis in myeloma cells associated with MYC downregulation and HEXIM1 upregulation. Preclinical functional and pharmacologic profiling of I-BET762 supports its use in phase 1 clinical studies.

1 December 2002 in Molecular Cell
Verified
Journal Article
Closed access
NHNicola Harker
Nicola Harker
TNTaku Naito
Taku Naito
MCMarta Cortes
Marta Cortes
AHArnd Hostert
Arnd Hostert
SHSandra Hirschberg
Sandra Hirschberg
DKDimitris Kioussis
Dimitris Kioussis

31 July 2012 in Science Signaling
Verified
Journal Article
Closed access
PDF file
APAmisha Patel
Amisha Patel
NHNicola Harker
Nicola Harker
LMLara Moreira-Santos
Lara Moreira-Santos
MFManuela Ferreira
Manuela Ferreira
KAKieran Alden
Kieran Alden
HVHenrique Veiga-Fernandes
Henrique Veiga-Fernandes
During the early development of the gastrointestinal tract, signaling through the receptor tyrosine kinase RET is required for initiation of lymphoid organ (Peyer’s patch) formation and for intestinal innervation by enteric neurons. RET signaling occurs through glial cell line–derived neurotrophic factor (GDNF) family receptor α co-receptors present in the same cell (signaling in cis). It is unclear whether RET signaling in trans, which occurs in vitro through co-receptors from other cells, has a biological role. We showed that the initial aggregation of hematopoietic cells to form lymphoid clusters occurred in a RET-dependent, chemokine-independent manner through adhesion-mediated arrest of lymphoid tissue initiator (LTin) cells. Lymphoid tissue inducer cells were not necessary for this initiation phase. LTin cells responded to all RET ligands in trans, requiring factors from other cells, whereas RET was activated in enteric neurons exclusively by GDNF in cis. Furthermore, genetic and molecular approaches revealed that the versatile RET responses in LTin cells were determined by distinct patterns of expression of the genes encoding RET and its co-receptors. Our study shows that a trans RET response in LTin cells determines the initial phase of enteric lymphoid organ morphogenesis, and suggests that differential co-expression of Ret and Gfra can control the specificity of RET signaling.

1 October 1997 in Immunity
Verified
Journal Article
Closed access
AHArnd Hostert
Arnd Hostert
MTMauro Tolaini
Mauro Tolaini
KRKathleen Roderick
Kathleen Roderick
NHNicola Harker
Nicola Harker
TNTrisha Norton
Trisha Norton
DKDimitris Kioussis
Dimitris Kioussis